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ABSTRACT
Background
Acute renal failure from ischemia significantly contributes to morbidity and mortality in
clinical settings, and strategies to improve renal resistance to ischemia are urgently needed.
Here, we identified a novel pathway of renal protection from ischemia using ischemic
preconditioning (IP).
Methods and Findings
For this purpose, we utilized a recently developed model of renal ischemia and IP via a
hanging weight system that allows repeated and atraumatic occlusion of the renal artery in
mice, followed by measurements of specific parameters or renal functions. Studies in gene-
targeted mice for each individual adenosine receptor (AR) confirmed renal protection by IP in
A1
 / , A2A
 / ,o rA3AR
 / mice. In contrast, protection from ischemia was abolished in A2BAR
 / 
mice. This protection was associated with corresponding changes in tissue inflammation and
nitric oxide production. In accordance, the A2BAR-antagonist PSB1115 blocked renal protection
by IP, while treatment with the selective A2BAR-agonist BAY 60–6583 dramatically improved
renal function and histology following ischemia alone. Using an A2BAR-reporter model, we
found exclusive expression of A2BARs within the reno-vasculature. Studies using A2BAR bone-
marrow chimera conferred kidney protection selectively to renal A2BARs.
Conclusions
These results identify the A2BAR as a novel therapeutic target for providing potent
protection from renal ischemia.
The Editors’ Summary of this article follows the references.
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Acute renal failure is deﬁned as a rapid decrease in the
glomerular ﬁltration rate (GFR), occurring over a period of
minutes to days [1]. The causes of acute renal failure are
classically divided into three categories, prerenal, postrenal,
or intrinsic [1]. However, over 50% of hospitalized patients
with acute renal failure suffer from renal ischemia leading to
prerenal azotemia or ‘‘intrinsic’’ acute tubular necrosis [2]. In
fact, a recent study of hospitalized patients revealed that only
a mild increase in the serum creatinine level (0.3–0.4 mg/dl) is
associated with a 70% greater risk of death than in persons
without any increase [3]. Along these lines, surgical proce-
dures requiring cross-clamping of the aorta and renal vessels
are associated with a renal failure rate of up to 30% [4].
Similarly, acute renal failure after cardiac surgery occurs in
up to 10% of patients under normal circumstances and is
associated with dramatic increases in mortality [5]. Taken
together, these data highlight the urgent need for additional
therapeutic modalities to prevent renal injury from ischemia
[6–8].
Extracellular adenosine has been implicated as a critical
mediator of reno-vascular functions [9,10]. In most vascular
beds adenosine causes vasodilatation (e.g., in the coronary
circulation), thereby contributing to the metabolic control of
organ perfusion [11]. In contrast, adenosine can cause
vasoconstriction in the kidneys, a response that has been
suggested to be an organ-speciﬁc version of metabolic control
designed to restrict organ perfusion when transport work
increases [9,10]. In addition, several studies of tissue
protection from limited oxygen availability have suggested
an anti-inﬂammatory and tissue protective role of extrac-
ellular adenosine, particularly during conditions of hypoxia
[12–18]. Extracellular adenosine is derived mainly via
enzymatic phosphohydrolysis of precursor nucleotides to
adenosine. In fact, recent studies of mice with genetic
deletion of enzymatic steps in extracellular adenosine
generation revealed that these mice are more prone to renal
ischemia (cd39
 /  or cd73
 /  mice) compared to their litter-
mate controls [19,20]. Once released into the extracellular
space, adenosine can activate four individual G-protein
coupled receptors (A1AR, A2AAR, A2BAR, and A3AR). As
such, previous studies have shown a critical role of
extracellular adenosine generation and signaling in tissue
protection from hypoxia [21–25] or during preconditioning
[19,20,26–28], where pretreatment with short and repeated
episodes of nonlethal ischemia (ischemic preconditioning
[IP]) result in a robust protection from subsequent ischemic
injury. At present, it remains unclear which ARs mediate
renal protection from ischemia. Some studies suggest a role
of signaling through myeloid A2AAR in renal protection [29],
other studies found signaling through the A1AR in inhibiting
renal inﬂammation and necrosis [30].
Similarly to studies of renal protection by IP, previous
studies in the heart have shown a critical role of extracellular
adenosine generation in IP-dependent cardioprotection. For
example, gene-targeted mice for cd39 [27] or cd73 [28] are not
protected by cardiac IP-treatment. Moreover, a recent study
compared myocardial infarct sizes in gene-targeted mice for
each individual adenosine receptor (AR) and found a pivotal
role of the A2BAR in attenuating ischemia-induced myocar-
dial cell death [28]. In addition to its tissue-protective effects,
extracellular adenosine signaling has been implicated in
several cardio-speciﬁc functions including A1AR-dependent
changes in cardiac conduction and heart rhythm (e.g.,
changes in P-R interval, atrio-ventricular blockade) [31],
release of natriuretic peptide by cardiac myocytes [32], or
the regulation of coronary blood ﬂow by A2A or A2BARs [11].
In contrast, different functions of extracellular adenosine
have been identiﬁed in the kidneys. For example, extrac-
ellular adenosine generation and signaling has been shown as
a critical control point in the regulation of the tubulo-
glomerular-feedback mechanisms, particularly through acti-
vation of the A1AR [10,33,34]. While adaptation of cardiac
myocytes trigged by adenosine, bradykinin, and opioids—
leading to activation of protein kinase C (PKC)—is central to
cardiac IP [35,36], ischemic injury of the kidneys is
characterized by vascular and renal-tubular injury [37,38],
suggesting that preconditioning phenomena of the kidneys
represent a form of vascular or reno-tubular adaptation.
Therefore, previous studies of adenosine in IP-dependent
cardioprotection have focused on histological assessment of
myocardial cell death or leakage of myocardial speciﬁc
enzymes into the systemic circulation [27,28,39], while studies
of extracellular adenosine in reno-protection by IP require
assessment of speciﬁc renal functions (e.g., glomerular
ﬁltration, tubular absorption, or secretion). Therefore, we
recently developed a murine model of in situ IP and ischemia
of the kidneys using a hanging weight system that allows
repeated and atraumatic occlusion of the renal artery in
mice, followed by measurements of speciﬁc parameters or
renal function (e.g., GFR, creatinine clearance, urine pro-
duction) to study molecular pathways of innate renal
protection from ischemia [40].
In the present studies, we utilized renal IP as an
experimental strategy to identify adenosine signaling path-
ways to increase renal resistance to ischemia. Here, we
studied gene-targeted mice for each individual AR for renal
protection by IP.
Methods
Mice
All animal protocols were in accordance with the German
guidelines for use of living animals and were approved by the
Institutional Animal Care and Use Committee of the
Tu ¨bingen University Hospital and the Regierungspra ¨sidium
Tu ¨bingen or the University of Colorado guidelines for animal
care. In pharmacological studies, C57BL/6J mice obtained
from Charles River Laboratories were used. Mice deﬁcient in
A1AR, A2BAR,o rA3AR on the C57BL/6 strain, or deﬁcient in
A2AAR on the CD1 strain were generated, validated, and
characterized as described previously [28,41–43]. For bone
marrow chimeric studies, mice deﬁcient in the A2AAR were
backcrossed over six generations to C57BL/6. In all control
experiments, age-, gender-, and weight-matched littermate
controls were used. In subsets of experiments, a previously
described A2BAR reporter mouse on the C57BL/6 strain was
used (A2BAR-knock-out [KO]/b-gal–knock-in mice) [44].
Murine Model for Renal IP
Mice underwent right nephrectomy followed by left renal
artery ischemia with or without prior IP treatment (four
cycles of 4 min ischemia and 4 min reperfusion prior to 45
PLoS Medicine | www.plosmedicine.org June 2008 | Volume 5 | Issue 6 | e137 0969
A2BAR in Renal Protection from Ischemiamin of ischemia) using a hanging weight system, as previously
described [40]. At the end of surgery, mice received 0.3 ml
normal saline IP and were allowed to recover for 2 h under a
heating lamp. Thereafter mice were placed into metabolic
cages (Tecniplast Deutschland) for evaluation of renal
function for 24 h, or mice were kept in standard cages for
performing inulin clearance on the next day.
Assessment of Renal Function
Plasma and urine creatinine were measured 24 h after renal
ischemia using a commercially available colorimetric method
(LT-SYS, LaborþTechnik). From these data we calculated the
creatinine clearance. Plasma and urine concentrations of Na
þ
and K
þ were determined with a ﬂame-emission photometer
(ELEX 6361, Eppendorf AG). Renal excretory and hemody-
namic values were calculated using standard formulas.
Kidneys were harvested after 24 h and stored at  80 8C until
further analysis.
Inulin Clearance
Inulin clearance was measured 24 h after renal ischemia (45
min, with or without prior IP treatment) as described
previously [33,45]. Brieﬂy, mice were anaesthetized using 50
mg/kg IP pentobarbital. Animals were then placed on a
temperature-controlled operating table to keep rectal tem-
perature at 37 8C. Tracheotomy was performed as described
previously [39], and the right jugular vein was cannulated for
continuous infusion. Blood samples were taken via a catheter
inserted into the left femoral artery. A catheter was placed in
the urinary bladder for timed urine collection after removal
of the right kidney. After the surgery, all mice received a
bolus of 0.85% sodium chloride solution in an amount equal
to 20% of body weight. Continuous infusion was maintained
at a rate of 600 ll/h/30g body weight, and
3H-inulin was added
to the infusion for evaluation of whole kidney GFR. After
stabilization of the animals for 20 min, 20-min timed urine
collections were performed for determination of urinary ﬂow
rate and
3H-inulin. Blood was obtained in the middle of every
urine collection period for measurement of
3H-inulin.
Concentration of
3H-inulin in plasma and urine were
performed by liquid phase scintillation counting, and GFR
was calculated by standard formulas.
Adenosine Measurement
Whole kidneys from cd73
 /  mice or age-, gender-, and
weight-matched littermates were removed and immediately
snap-frozen with clamps precooled to the temperature of
liquid nitrogen with or without IP treatment prior to
ischemia. The frozen kidneys were pulverized under liquid
nitrogen, and the tissue protein was precipitated with 0.6 N
ice-cold perchloric acid. Tissue adenosine levels were
determined via HPLC as described previously [46].
Renal Histology
Kidneys were excised and harvested 24 h following 45 min
of ischemia with or without IP in A2BAR
 /  and their wild-
type (WT) controls. Renal tissues were ﬁxed in 4.5% buffered
formalin, dehydrated, and embedded in parafﬁn. Sections (3
lm) were stained with hematoxylin and eosin (HE). For
evaluation of granulocytic inﬁltrates, sections were stained by
histochemistry using chloracetate esterase (CAE) as previ-
ously described [40]. Examination and scoring of three
representative sections of each kidney (n ¼ 4–6 for each
condition) were carried out blinded to the experimental
group as described previously [47,48].
Immunofluorescence Histochemistry
Kidneys were excised and harvested 24 h following 45 min
of ischemia with or without IP in A2BAR
 /  and their WT
controls. The samples were cut in 5-lm slices, mounted on
superfrost glass slides for immunohistochemistry, and stored
at  20 8C. Immunoﬂuorescence histochemistry was carried
out using primary polyclonal rabbit anti-inducible nitric
oxide synthase (iNOS) antibody (anti macNOS,Transduction
Lab) at a 1:50 dilution in 1% bovine serum albumin (BSA) in
PBS. The slides were pretreated with 10% normal goat serum
for 1 h and then incubated in anti-iNOS antiserum at room
temperature for 1 h. As secondary antibodies, FITC-labeled
goat anti-rabbit antibodies (Dianova) were applied at 1:50
dilution in PBS at room temperature for 1 h. The primary
antibody was omitted on the slides that served as negative
controls. After mounting with Dako ﬂuorescent mounting
medium containing 15 Mm NaN3 (Dako-Patts), the slides
were assessed for ﬂuorescent microscopy. Expression of iNOS
in inﬂammatory cells was assessed in ten randomly selected
areas per sample, observed at 6003 magniﬁcation using a
scale system iNOS score: 0, no iNOS signal; 1, rare iNOS
expression in macrophages; 2, moderate iNOS expression in
three to ﬁve areas; 3, iNOS expression in ﬁve to eight areas; 4,
strong iNOS expression in macrophages in all selected areas.
Measurement of Nitrite/Nitrate Concentrations
Plasma and renal tissue concentrations of nitrite (NO2) and
nitrate (NO3) were measured using a colorimetric-assay kit
(Cayman Chemical Company).
Renal Tissue Nitric Oxide Synthase Activity
We measured nitric oxide synthase (NOS) activity in the
renal tissue with a commercially available kit (Calbiochem,
EMD Biosciences). The assay is based on the enzymatic
conversion of nitrite to nitrate reductase, followed by the
spectophotometric quantiﬁcation of nitrite levels using the
Griess reagent.
Myeloperoxidase Activity
To quantify neutrophil inﬁltration, we performed myelo-
peroxidase (MPO) measurements as previously described [40].
ELISA (NFjB, IjBa) from Renal Tissue
The snap-frozen kidneys were thawed, weighed, and trans-
ferred to different tubes on ice containing 1 ml of T-PER
(Tissue Protein Extraction Reagent, Pierce Biotechnology).
The renal tissues were homogenized at 4 8C. Renal homoge-
nates were centrifuged at 9,000 3 g for 10 min at 4 8C.
Supernatants were transferred to clean microcentrifuge
tubes, frozen on dry ice, and thawed on ice. Total protein
concentrations in the renal tissue homogenates were deter-
mined using a BCA (bicinchoninic acid) kit (Pierce Bio-
technology). Renal tissue homogenates were diluted with 50%
assay diluent and 50% T-PER reagent to a ﬁnal protein
concentration of 400 lg/ml. Activated NFjB (TransAM,
Active Motif North America) and IjBa (TransAM, Active
Motif North America) levels were measured in homogenates
from whole renal tissues using a mouse ELISA kit according
to the manufacturer’s instructions.
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For speciﬁc inhibition of the A2BAR, PSB1115 (Tocris,
Biotrend-Chemikalien) was administered IV via the jugular
vein (5 mg/kg/h). This dosing regimen was previously shown to
effectively inhibit A2BAR signaling [28]. In other experi-
ments, a recently described A2BAR agonist (BAY 60–6583,
Bayer HealthCare AG, 60 lg/kg IV via the jugular vein) was
used [28].
Transcriptional Analysis
For assessment of A1AR, A2AAR, A2BAR, and A3AR
transcript levels as well as tumor necrosis factor-alpha (TNF-
a), interleukin (IL)-6, keratinocyte-derived chemokine (KC, the
mouse ortholog of human IL-8), and IL-10 transcript levels,
total RNA was isolated and quantiﬁcation of transcript levels
were measured by real-time reverse transcription (RT)-PCR
(iCycler, Bio-Rad Laboratories Inc.). In short, total RNA was
isolated from renal tissue using the total RNA isolation
NucleoSpin RNA II Kit according to the manufacturer’s
instructions (Macherey & Nagel). For this purpose, liquid
nitrogen frozen tissue was homogenized in the presence of
RA1 lysis buffer (Micra D8 homogenizer, ART-Labortechnik),
and after ﬁltration, lysates were loaded on NucleoSpin RNA II
columns, followed by desalting and DNaseI digestion (Macher-
ey & Nagel). RNA was washed, and the concentration was
quantiﬁed. The PCR reactions contained 1 lMs e n s ea n d1lM
antisense oligonucleotides with SYBR Green I (Molecular
Probes Inc.). Primer sets (sense sequence, antisense sequence,
and transcript size, respectively) for the following genes were:
A1AR (59-AGG GAG GGG TCA AGA ACT GT-39,5 9-TCC CAG
TCT CTG CCT CTG TT-39, 109 bp); A2AAR (59-GAA GAC
CAT GAG GCT GTT CC-39,5 9-GAG TAT GGG CCA ATG
GGA GT-39, 253 bp); A2BAR (59-GGA AGG ACT TCG TCT
CTC CA-39,5 9-GGG CAG CAA CTC AGA AAA CT-39, 322 bp);
A3AR (59-CAA TTC GCT CCT TCT GTT CC-39,5 9-TCC CTG
ATT ACC ACG GAC TC-39, 334 bp); IL-6 (ACCGCTAT-
GAAGTTCCTCTC, CTCTCCGGACTTGTGAAGTA); TNF-a
(ACTCCAGGCGGTGCCTATGT, TCCAGCTGCTCCTC-
CACTTG); IL-10 (CTTACTGACTGGCATGAGGA, GCAT-
TAAGGAGTCGGTTAGC); KC (CCAAGCCTTGA-
fj;GTCACAGAG, GGACAGCATCTGGCAGAATA). Each target
sequence was ampliﬁed using increasing numbers of cycles of
94 8C for 1 min, 58 8C (for cytokines 60 8C) for 0.5 min, 72 8C
for 1 min. Murine b-actin mRNA (sense primer, 59-ACA TTG
GCA TGG CTT TGT TT-39 and antisense primer, 59-GTT TGC
TCC AAC CAA CTG CT-39) was ampliﬁed in identical
reactions to control for the amount of starting template.
Immunoblotting Experiments
In subsets of experiments, we determined renal A2BAR
protein content. For this purpose, C57BL/6J mice were
humanely killed following renal IP as above, and the kidney
was excised at indicated time points (60, 120, and 240 min
after IP) and immediately frozen at  80 8C. Tissues were
homogenized and lysed for 10 min in ice-cold lysis buffer (150
mM NaCl, 25 mM Tris [pH 8.0], 5 mM EDTA, 2% Triton X-
100, and 10% mammalian tissue protease inhibitor cocktail,
Sigma-Aldrich), and collected in microfuge tubes. After
spinning at 14,000 3 g to remove cell debris, the pellet was
resuspended in reducing Laemmli sample buffer and heated
to 90 8C for 5 min. Samples were resolved on a 12%
polyacrylamide gel and transferred to nitrocellulose mem-
branes. The membranes were blocked for 1 h at room
temperature in PBS supplemented with 0.2% Tween 20 (PBS-
T) and 4% BSA. The membranes were incubated in 10 lg/ml
A2BAR goat polyclonal antibody raised against the C
terminus (Santa Cruz) for 1 h at room temperature, followed
by 10 min washes in PBS. The membranes were then
incubated in 1:3,000 HRP-donkey anti-goat Ig for A2BAR
detection (Santa Cruz). The wash was repeated, and proteins
were detected by enhanced chemiluminescence (Applied
Biosystems). To control for protein loading, blots were
stripped in stripping buffer for 15 min, washed ones for 10
min with TBST, and membrane was blocked for 1 h at room
temperature in PBS supplemented with 0.2% Tween 20 (PBS-
T) and 4% BSA. Thereafter the membrane was incubated
with b-actin using a mouse monoclonal anti-human b-actin
antibody (Abcam Inc.). The protein levels of b-actin were
detected by enhanced chemiluminescence.
Analysis of b-Galactosidase Expression in Renal Sections of
A2BAR Reporter Mice
To localize the A2BAR in renal tissues, we analyzed b-
galactosidase expression in renal sections in A2BAR-KO/b-
gal–knock-in mice. Mice were anesthetized with isoﬂurane
and perfused through the left heart ventricle with 20 ml of
PBS (pH 7.4) at a rate of 4 ml/min. Perfusion for ﬁxation with
30 ml of freshly made 2% paraformaldehyde in PBS (pH 7.4)
was continued for 15 min at 2 ml/min and was followed by
perfusion with PBS for 10 min. Kidneys were dissected from
the perfused mouse and stored in ice-cold PBS, prior to
staining for b-galactosidase activity. Kidneys were cut into 1–
2-mm thick slices, and stained with X-gal staining solution (5
mM K3Fe[CN]6, 5 mM K4Fe[CN]6 3 3H2O, [Sigma Aldrich,
catalogue numbers P-8131 and P-9287, respectively], 2 mM
MgCl2, in PBS) containing a ﬁnal concentration of 1 mg/ml 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal,
American Bioanalytical, catalogue number AB02400-1000).
Samples were incubated at 37 8C for 2–4 h on a rocking
platform. After staining, samples were rinsed with PBS and
stored in 4% paraformaldehyde at 4 8C. Samples were
embedded in parafﬁn and cut at a thickness of 5 lm.
Thereafter sections were stained with HE.
Generation of Bone Marrow Chimeric Mice
This animal protocol was in accordance with the German
guidelines for use of living animals and was approved by the
Institutional Animal Care and Use Committee of the
Tu ¨bingen University Hospital and the Regierungspra ¨sidium
Tu ¨bingen or the University of Colorado guidelines for animal
care. To deﬁne the contribution of renal or hematopoietic
A2BARs during renal ischemia or IP, we generated bone
marrow chimeric mice in which bone marrow was ablated by
radiation in WT mice (C57BL/6) followed by reconstitution
with bone marrow derived from previously characterized
mice gene-targeted for the A2BAR [28] and vice versa
(A2BAR
 /  ! A2BAR
þ/þ, A2BAR
þ/þ ! A2BAR
 / ). Experiments
with A2BAR
þ/þ ! A2BAR
þ/þ and A2BAR
 /  ! A2BAR
 /  mice
served as controls. Since myeloid A2AAR signaling has been
suggested in the attenuation of renal ischemia injury [29], we
also performed IP in A2BAR
þ/þor A2BAR
 / transplanted with
bone marrow from A2AAR
þ/þ or A2AAR
 /  mice. In short,
male donor mice (8–10 wk old, 20–25 g) were humanely killed,
and the marrow from the tibia and femur were harvested by
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chloride solution. The bone marrow cells were then centri-
fuged at 400g for 5 min, resuspended, and counted. Recipient
mice (8–10 wk of age, 20–25 g) were irradiated with a total
dose of 12 Gy from a
137Cs source. Immediately after
irradiation, 10 3 10
6 BM cells/recipient were injected in 0.3
ml 0.9% sodium chloride into the jugular vein. The resulting
chimeric mice were housed in microisolators for at least 7 wk
before experimentation and fed with water containing
tetracycline (100 mg/l) in the ﬁrst 2 wk following BM
transplantation. Consistent with other studies using a similar
approach [49], preliminary experiments using the same
conditioning regimen and transplanting CD45.1
þ bone
marrow into irradiated CD45.1
  mice resulted in .95%
chimerism in B cells, neutrophils, and monocytic cells, and
;85% chimerism in CD4þand CD8þT cells of recipient mice
(unpublished data).
Data Analysis
Renal injury score data are given as median and range, all
other data are presented as mean 6 SD. Renal injury was
analyzed with the Kruskal-Wallis test, with follow-up pairwise
comparisons by Wilcoxon-Mann-Whitney test. For all other
outcomes, one-way ANOVA was used to perform compar-
isons among groups. A signiﬁcant (p , 0.05) overall F-statistic
was followed by Tukey’s post-hoc, pairwise multiple compar-
ison test. For the comparison of the different AR transcripts,
pairwise comparisons were made between the control and
treatment groups by Dunnett multiple comparison techni-
que. All test are two-sided, with signiﬁcance set at p   0.05.
SPSS version 16.0.1 was used to perform all calculations.
Results
Extracellular Adenosine Levels Are Elevated with Renal IP
Treatment
Previous studies have suggested extracellular adenosine in
renal protection by IP [19,27,50–52]. Therefore, we ﬁrst
measured renal adenosine levels in preconditioned or un-
preconditioned renal tissues. As shown in Figure 1, renal
adenosine tissue content was approximately 10-fold higher
after renal IP as compared to baseline. Similarly, renal
adenosine levels were also elevated in IP-treated renal tissues
after 45 min of ischemia. To conﬁrm the extracellular nature
of these ﬁndings, we repeated this experiment in previously
characterized mice deﬁcient of cd73 [23,52]. In fact, CD73
metabolizes the extracellular conversion of adenosine mono-
phosphate (AMP) to adenosine, and thus represents the pace-
maker enzyme of extracellular adenosine generation [53]. We
found that renal adenosine content in cd73
 /  mice with IP or
IP prior to ischemia was signiﬁcantly lower compared to
littermate controls, thereby conﬁrming the extracellular
nature of IP-dependent adenosine elevations. Taken togeth-
er, these studies demonstrate extracellular elevations of
adenosine with renal IP treatment.
IP Is Selectively Abolished in A2BAR
 /  Mice
To elucidate adenosine signaling pathways through individ-
ual ARs, we exposed previously described A1AR
 /  [42],
A2AAR
 /  [43], A2BAR
 /  [28], and A3AR
 /  [41], mice to renal
IP prior to ischemia. For this purpose, mice were subjected to
45 min of renal artery occlusion with or without prior IP (four
cycles, 4 min ischemia, 4 min reperfusion) followed by 24 h of
reperfusion until assessment of renal function. To avoid
surgical trauma during the procedure, we utilized a recently
described model of intermittent renal artery occlusion via a
hanging-weight system for isolated renal artery occlusion [40].
As shown in Figure 2A–2D, plasma creatinine and GFR,
assessed by inulin clearance, were improved by IP in all gene-
targeted mice for individual ARs to a similar degree as their
respective littermate control mice, with the notable exception
of A2BAR
 /  mice. In fact, attenuation of plasma creatinine
and improved GFR with IP were completely abolished in
A2BAR
 /  mice (Figure 2C). In addition, the renal protective
Figure 1. Renal Adenosine Tissue Content with IP Treatment with or
without Subsequent Ischemia
Age-, gender-, and weight-matched cd73
 /  mice or littermate controls
(WT) were subjected to IP alone (IP) or IP followed by 45 min of ischemia
(IPþI) using a hanging weight system for atraumatic occlusion of the left
renal artery. The IP protocol consisted of four cycles of ischemia and
reperfusion (4 min each).
Statistics: One-way ANOVA was used to perform comparisons among
groups. The F-test results are F (5,22)¼210.34, p , 0.001. All statistically
significant differences within groups were compared by Tukey’s post-hoc
test (p , 0.05) and were indicated with a bracket (*, p , 0.01; **, p ,
0.001).
doi:10.1371/journal.pmed.0050137.g001
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urinary ﬂow rate (Figure 3B), urinary excretion of sodium
(Figure 3C), or potassium (Figure 3D) were abrogated following
targeted deletion of the A2BAR. To conﬁrm the absence of
renal protection of IP in A2BAR
 /  mice on a histological
evaluation depicts level, we examined kidneys from WT or
A2BAR
 /  mice after 45 min of ischemia with and without
previous IP (control: Figure 3E, WT without IP; Figure 3F, WT
with IP; Figure 3G). Histological intact tubular cell morphology
in kidneys with IP prior to ischemia (WT þ IP) in contrast to
kidneys without IP (WT   IP). Here, severe acute tubular
necrosis—obvious from the loss of tubular cell nuclei (arrow in
Figure 3F) in the cortex and outer medulla with destruction of
the proximal tubular brush border—was observed (Figure 3F).
In addition, hyaline cast formation, intraluminal necrotic
cellular debris (arrow in Figure 3F), and casts containing brush
border blebs could be seen in the cortex as well as in the outer
medulla. In contrast, these signs of tubular damage were only
sporadic and quantitatively mild in mice with IP (Figure 3G).
Semiquantitative histological analysis demonstrated a reduc-
tion in the Jablonski index from 4 (range 3–4) without IP to 2
(range 1–3, Figure 3J, p , 0.05) with IP. This obvious
improvement of renal histology by IP was completely abolished
in A2BAR
 /  mice (Figure 3H and 3I). Taken together, these
data provide the ﬁrst functional evidence for a critical role of
the A2BAR in renal protection by IP.
Figure 2. Renal Ischemia and Preconditioning in Gene-Targeted Mice for Individual ARs
(A–D) Previously characterized A1AR
 / , A2AAR
 / , A2BAR
 / , and A3AR
 / mice or their respective age-, weight-, and gender-matched littermate controls
(WT) were subjected to right nephrectomy followed by 45 min of left renal artery ischemia with or without prior in situ IP (consisting of four cycles of 4
min ischemia followed by 4 min reperfusion). Plasma creatinine and GFR (as measured by inulin clearance) were obtained after 24 h of reperfusion.
Note: Renal protection conferred by IP is abrogated in A2BAR
 /  mice.
Statistics: One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.001 versus WTþIP; **, p , 0.001 versus the respective gene targeted mice
with IP). The F-test results are for plasma creatinine: (A) F (3,21)¼41.2, p , 0.001; (B) F (3,23)¼60.66, p , 0.001; (C) F (3,22)¼67.87, p , 0.001; (D) F (3,25)
¼48.45, p , 0.001; and for GFR (A) F (3,20)¼79.34, p , 0.001; (B) F (3,21)¼59.12, p , 0.001; (C) F (3,22)¼109.75, p , 0.001; (D) F (3,22)¼93.43, p , 0.001.
doi:10.1371/journal.pmed.0050137.g002
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A2BAR in Renal Protection from IschemiaAnti-inflammatory Effects of IP Are Abrogated in A2BAR
Deficient Mice
After having shown that A2BAR
 / mice are not protected by
renal IP, we next attempted to understand how A2BAR
signaling can affect renal IP. Here, we considered a study
showing an anti-inﬂammatory role of A2BAR signaling in
hypoxic preconditioning [26]. In fact, Khoury et al. demon-
strated that adenosine-dependent signaling pathways inhibit
NFjB activation during preconditioning [26]. Based on the
hypothesis, that A2BAR signaling may be critical in mediating
anti-inﬂammatory effects of IP, we assessed renal inﬂammatory
cell accumulation during ischemia. As shown in Figure 4A–4E,
45 min of renal ischemia followed by 24 h of reperfusion was
associated with dramatic increases in renal granulocyte
accumulation as shown in histological sections (Figure 4A–
4E), granulocyte score (Figure 4F), and measurement of the
Figure 3. Renal Function and Histology in A2BAR
 /  Mice Exposed to Renal Ischemia or Preconditioning
A2BAR
 /  or age-, weight-, and gender-matched littermate controls (WT) were subjected to right nephrectomy followed by 45 min of left renal artery
ischemia with or without prior in situ IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion).
Renal function tests and renal histology were obtained after 24 h of reperfusion. (A) Creatinine clearance.
(B) Urinary flow rate.
(C) Urinary sodium excretion.
(D) Urinary potassium excretion.
(E–I) Representative HE staining (4003and 8003). Tissue damage was characterized by loss of tubular cells, tubular cast, and tubular dilation (arrows).
Slice thickness was 3 lm.
(J) Quantification of histological tissue damage assessed by Jablonski index.
Statistics: (A–D) One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.001 versus WTþIP; **, p , 0.001 versus the A2BAR
 / mice with IP).
The F-test results are (A) F (4,28) ¼ 207.93, p , 0.001; (B) F (4,26) ¼ 50.96, p , 0.001; (C) F (4,25) ¼ 57.65, p , 0.001; (D) F (4,25) ¼ 57.65, p , 0.001.
(J) Kruskal-Wallis nonparametric analysis (chi-square¼17.175, degree of freedom (df)¼4, p¼0.002) with follow-up pairwise comparisons by Wilcoxon-
Mann-Whitney test was performed with *, p , 0.05 versus WT þ IP and **, p , 0.05 versus the A2BAR
 /  mice with IP.
doi:10.1371/journal.pmed.0050137.g003
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A2BAR in Renal Protection from Ischemiapolymorphonuclear leukocyte (PMN) marker myeloperoxidase
(MPO) (Figure 4G). Pretreatment with IP resulted in a
profound reduction in inﬂammatory cell accumulation. How-
ever, the anti-inﬂammatory effects of renal IP were completely
abolished in A2BAR
 /  mice. Along the same lines, renal
transcript of pro-inﬂammatory cytokines TNF-a, IL-6, and KC
were all attenuated following IP treatment of WT mice,
whereas no changes with IP occurred in A2BAR
 / mice (Figure
5A–5C). In contrast, transcript levels of the anti-inﬂammatory
cytokine IL-10 were elevated with IP treatment of WT mice,
whereas IP in gene-targeted mice for the A2BAR did not alter
renal IL-10 transcript levels (Figure 5D). Consistent with
previous studies showing adenosine signaling in inhibiting
NFjB activity [26], we found that increases of renal NFjB
activity with ischemia were attenuated following IP treatment
(Figure 5E). In contrast, IP-dependent inhibition of NFjB
activation was abrogated in A2BAR
 / mice (Figure 5E). While a
number of mechanisms have been suggested to mediate the
endogenous inactivation of NFjB, each of these pathways
converges on changes in the inducible degradation of IjB[ 5 4 ] .
Figure 4. Inflammatory Changes in A2BAR
 /  Mice during Renal Preconditioning
A2BAR
 /  mice and their respective age-, weight-, and gender-matched littermate controls (WT) were subjected to right nephrectomy followed by 45
min of left renal artery ischemia with or without prior in situ IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion).
(A–E) Chloracetate esterase staining. Arrows indicate granulocytes (magnification 6003).
(F) Quantification of granulocyte accumulation.
(G) Quantification of neutrophil tissue accumulation by measurement of myeloperoxidase (MPO).
Statistics: (F) Kruskal-Wallis nonparametric analysis (chi-square ¼ 17.86, df ¼ 4, p ¼ 0.001) with follow-up pairwise comparisons by Wilcoxon-Mann-
Whitney test was performed with *, p , 0.01 versus WT þ IP and **, p , 0.01 versus the A2BAR
 /  mice with IP.
(G) One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.001 versus WTþIP; **, p , 0.001 versus the A2BAR
 / mice with IP). The F-test
result is F (4,22) ¼ 46.26, p , 0.001.
doi:10.1371/journal.pmed.0050137.g004
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A2BAR in Renal Protection from IschemiaThus, we determined whether A2BAR signaling inﬂuences IjB
activity during IP. In fact, IP associated increase in renal IjB
activity were attenuated in A2BAR
 /  mice (Figure 5F). Taken
together, these studies reveal A2BAR-dependent anti-inﬂam-
matory effects of renal IP.
IP-Associated Attenuation of Nitric Oxide Pathways Is
Abolished in A2BAR
 /  Mice
Previous studies of renal ischemia revealed that ischemic
tissues and inﬁltrating inﬂammatory cells express iNOS and
release reactive oxygen species and N-derived oxidants [37].
As such, inhibition of iNOS attenuates ischemia reperfusion
injury [37]. In turn, oxidative stress is involved in the
pathogenesis of ischemia-reperfusion injury by adding
further insult to renal tissues and inducing the release of
pro-inﬂammatory molecules, which recruit inﬂammatory
cells into the interstitium [55]. Consistent with these studies,
we found signiﬁcant increases in plasma and renal tissue
levels of nitrite/nitrate with renal ischemia, which were
attenuated by IP-treatment (Figure 6A and 6B). However,
Figure 5. Transcriptional Responses of Inflammatory Cytokines Measured in Renal Tissue
A2BAR
 /  mice and their respective age-, weight-, and gender-matched littermate controls (WT) were subjected to right nephrectomy followed by 45
min of left renal artery ischemia with or without prior in situ IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion). (A) TNF-a, (B)
IL-6, (C) KC (mouse ortholog of human IL-8), and (D) IL-10 were assessed by real-time RT-PCR from renal tissues. Data were calculated relative to b-actin
and are expressed as fold change compared to sham-operated animals without IP treatment.
(E) NFjB and (F) IjBa levels were evaluated in renal tissue homogenates using a mouse enzyme-linked immunosorbent assay (ELISA).
Statistics: One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.001 versus WTþIP; #, p , 0.05 versus WTþIP; **, p , 0.001 versus the
A2BAR
 / mice with IP). The F-test results are (A) F (4,15)¼39.28, p , 0.001; (B) F (4,15)¼53.40, p , 0.001; (C) F (4,15)¼201.01, p , 0.001; (D) F (4,15)¼
61.46, p , 0.001; (E) F (4,15)¼ 75.76, p , 0.001; and (F) F (4,15) ¼ 56.18, p , 0.001.
doi:10.1371/journal.pmed.0050137.g005
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A2BAR in Renal Protection from Ischemiaattenuation by IP was abolished in gene-targeted mice for
the A2BAR (Figure 6A and 6B). Similarly, iNOS activity was
reduced in IP-treated renal tissues of A2BAR WT mice but
not in A2BAR
 /  mice (Figure 6C). Moreover, immuno-
histochemistry revealed a strong immune-reactivity for iNOS
in macrophages following ischemia. Macrophage inﬁltration
and iNOS expression was reduced following IP treatment of
WT but not of A2BAR
 /  mice (Figure 6D–6I). Taken
together, these studies suggest that IP-associated attenuation
of nitric oxide production involves signaling through the
A2BAR.
A2BAR Antagonist Treatment Abolishes Renal Protection
by IP
After having shown a critical role of A2BAR-signaling in
renal protection by IP in gene-targeted mice, we next
pursued pharmacological approaches. For this purpose, we
administered a highly selective, water soluble A2BAR
Figure 6. Nitrite, Nitrate Plasma Concentrations, and Renal Tissue Content and Nitric Oxide Synthetase Activity in Renal Tissues
A2BAR
 /  mice and their respective age-, weight-, and gender-matched littermate controls (WT) were subjected to right nephrectomy followed by 45
min of left renal artery ischemia with or without prior in situ IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion). (A) Plasma or
(B) tissue concentrations of nitrite (NO2) and nitrate (NO3) were measured using colorimetric-assay kits.
(C) Tissue nitric oxide synthetase (NOS) activity.
(D–H) Immunohistochemical staining for iNOS.
(I) iNOS expression score.
Statistics: (A–C) One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.001 versus WTþIP; **, p , 0.001 versus the A2BAR
 / mice with IP).
The F-test results are (A) F (4,22) ¼ 89.90, p , 0.001; (B) F (4,30) ¼ 32.41, p , 0.001; (C) F (4,25) ¼ 36.54, p , 0.001.
(I) Kruskal-Wallis nonparametric analysis (chi-square¼19.1, df¼4, p¼0.001) with follow-up pairwise comparisons by Wilcoxon-Mann-Whitney test was
performed with *, p , 0.01 versus WT þ IP and **, p , 0.05 versus the A2BAR
 /  mice with IP.
doi:10.1371/journal.pmed.0050137.g006
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A2BAR in Renal Protection from Ischemiaantagonist PSB1115 [56] and treated WT mice with intra-
venous PSB1115, 5 mg/kg/h, a dose we had previously shown
to be effective in inhibiting the murine A2BAR in vivo [28].
To determine a time-window of PSB115 in attenuating renal
IP-protection, we administered PSB1115 or vehicle prior to
the surgery, before ischemia, and 5 min and 2 h after
ischemia. As shown in Figure 7, renal protective effects of IP
on plasma creatinine (Figure 7A) and on GFR (Figure 7B)
were abolished with PSB1115 treatment, when given before
or early during reperfusion. These pharmacological studies
conﬁrm the critical role of A2BAR signaling for renal
protection by IP.
A2BAR Agonist (BAY 60–6583) Improves Renal Function
during Ischemia
After having shown that selective inhibition of the A2BAR
attenuates renal protection by IP, we next pursued a
potential therapeutic role of a speciﬁc A2BAR agonist (BAY
60–6583). In fact, a recent study demonstrated selectivity and
functional in vivo evidence of this compound [28]. Here, we
treated C57BL/6J mice with a single intravenous bolus of BAY
60–6583 (60 lg/kg body weight) prior to the surgical
procedure, directly before renal ischemia, and 5 min or 2 h
after ischemia. BAY 60–6583 treatment resulted in a dramatic
improvement of GFR (Figure 8A) and plasma creatinine levels
(unpublished data). When this experiment was repeated in
A2BAR
 /  mice, no improvement in GFR was found (Figure
8A), conﬁrming the speciﬁcity of the renal protective effects
of BAY 60–6583 through A2BAR signaling. Semiquantitative
histological analysis conﬁrmed severe acute tubular necrosis
without BAY 60–6583 treatment in WT mice (Jablonski index
of 3, range 3–4, Figure 8B–8D). Treatment with BAY 60–6583
was associated with a signiﬁcant attenuation of tubular
destruction (Jablonski index of 2, range 1–3, p , 0.05, Figure
8B–8D). In contrast A2BAR
 /  mice showed no reduction in
tubular damage with BAY 60–6583 treatment (Figure 8B–8D).
Moreover, renal protection from ischemia with BAY 60–6583
treatment was limited to a time window that ended during
early reperfusion. Taken together, these studies provide
strong rationale for therapeutically targeting the A2BAR
during renal ischemia.
Renal IP Is Associated with Selective Induction of the
A2BAR
After having demonstrated A2BAR-dependent signaling
pathways in renal protection by IP, we next investigated
transcriptional consequences of renal IP on expressional
levels of all four ARs. For this purpose, renal tissues were
harvested at indicated time points following IP-treatment
and transcript levels of individual ARs were determined by
real-time RT-PCR (Figure 9A–9D). These studies revealed
prompt and selective induction of the A2BAR transcript
following renal IP (approximately 6-fold induction 60 min
after IP, p , 0.05, Figure 9C). In contrast, mRNA levels for the
A1AR, A2AAR, and A3AR remained unchanged following 60,
120, or 240 min of IP (Figure 9A, 9B, and 9D). In addition,
Western blot analysis of A2BAR protein from preconditioned
renal tissues conﬁrmed A2BAR induction (Figure 9E).
Consistent with previous work showing selective A2BAR
induction with vascular hypoxia [24] or myocardial IP [28],
these studies reveal induction of A2BAR transcript and
protein with renal IP treatment.
Studies in A2BAR Reporter Mice Confer A2BAR Expression
to the Reno-Vasculature
On the basis of the above studies showing induction of the
renal A2BAR with preconditioning, we were interested to
deﬁne, which tissues express the A2BAR within the kidneys.
Here, we used a previously characterized A2BAR reporter
mouse (A2BAR-KO/b-gal–knock-in mice) or their respective
littermate control mice [44]. Surprisingly, b-gal staining could
only be detected within the reno-vasculature. In contrast,
Figure 7. Pharmacological Studies of A2BAR Signaling during Renal
Ischemia and Preconditioning
A2BAR antagonist (PSB1115): Age-, weight-, and gender-matched C57BL/
6J underwent right nephrectomy. Prior to the surgery, immediately
before ischemia, 5 min or 2 h after ischemia, they received the selective
A2BAR antagonist PSB1115 (5 mg/kg, intravenous) or treatment with a
vehicle control. They were exposed to 45 min of left renal artery ischemia
with or without prior in situ IP (consisting of four cycles of 4 min
ischemia followed by 4 min of reperfusion). (A) Plasma creatinine and (B)
GFR as assessed by inulin clearance were obtained after 24 h of
reperfusion.
Statistics: One-way ANOVA with Tukey’s post-hoc test was performed (*,
p , 0.001 versus the respective group without IP; **, p , 0.001 versus
WT mice with IP and with PSB115 treatment). The F-test results are (A) F
(9,54) ¼ 42.20, p , 0.001; (B) F (9,55) ¼ 51.67, p , 0.001.
doi:10.1371/journal.pmed.0050137.g007
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A2BAR in Renal Protection from IschemiaFigure 8. A2BAR Agonist (BAY 60–6583). A2BAR
 /  Mice or Age-, Weight-, and Gender-Matched Littermate Controls Underwent Right Nephrectomy
followed by 45 min of Left Renal Artery Ischemia and 24 h of Reperfusion
They underwent treatment with BAY 60–6583 (60 lg/kg intravenous) or vehicle control given before the surgery, immediately before ischemia, 5 min or
2h after ischemia.
(A) GFR (as measured by inulin clearance and (B) Jablonski index for histological quantification of ischemic injury were obtained after 24 h of
reperfusion.
(C, D) Representative HE staining (4003 and 8003) of renal histology following 45 min of ischemia with (þBAY) or without BAY 60–6583 ( BAY) given
prior to ischemia are displayed.
Statistics: (A) One-way ANOVA with Tukey’s post-hoc test was performed (*, p , 0.01 versus the WT mice with BAY treatment, **, p , 0.001 versus WT
mice with BAY treatment). The F-test results are (A) F (11,69) ¼ 54.84, p , 0.001.
(B) Kruskal-Wallis nonparametric analysis (chi-square¼61.08, df¼11, p , 0.001) with follow-up pairwise comparisons by Wilcoxon-Mann-Whitney test
was performed with *, p , 0.01 versus WT mice with BAY treatment.
doi:10.1371/journal.pmed.0050137.g008
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A2BAR in Renal Protection from Ischemiarenal epithelia stained negative for the A2BAR (Figure 9F–9I).
Taken together, these studies reveal for the ﬁrst time, to our
knowledge, a selective reno-vascular expression of the A2BAR
within the kidneys.
Renal IP in A2BAR Bone-Marrow Chimeric Mice
On the basis of these studies showing reno-vascular
expression of the A2BAR and other studies showing myeloid
A2BAR expression, particularly on macrophages [44], we
Figure 9. Transcriptional Responses to Renal IP and Expression of the A2BAR within the Kidneys
(A–D) Age-, gender-, and weight-matched C57BL/6J mice were subjected to right nephrectomy followed by in situ IP with a hanging weight system for
atraumatic occlusion of the left renal artery. The IP protocol consisted of four cycles of ischemia/reperfusion (4 min each), followed by indicated times of
reperfusion. Transcriptional responses of the A1AR, A2AAR, and A2BAR of the A3AR were assessed by real-time RT-PCR. Data were calculated relative to
b-actin and are expressed as fold change compared to sham-operated animals without IP treatment.
(E) Western blotting for renal A2BAR following IP treatment. Kidneys were excised at indicated times, flash frozen, and lysed; proteins were resolvedb y
SDS PAGE and transferred to nitrocellulose. Membranes were probed with anti-A2BAR antibody. The same blot was reprobed for b-actin as a control for
protein loading. One representative experiment of three is shown.
(F–I) A previously described A2BAR reporter mouse was used (A2BAR-KO/b-gal–knock-in mice). Renal tissues were prepared and stained for b-
galactosidase (b-Gal) as indicative of the A2BAR gene promoter, which drives the expression of this reporter gene. Procedures are as detailed under
Methods. (F, G) b-Gal staining of kidney derived from littermate controls (WT) or A2BAR
 /  mice, and captured at the indicated magnifications (16 3)
with an Olympus IX70 microscope combined with Hamamatsu charge-coupled device camera C4742–95.
(H, I) HE-staining histological examination of renal sections derived from the kidney shown in upper panel. Arrows point to b-Gal stained blood vessels.
Fold magnification of captured images are 6003. WT mice were subjected to similar staining showing no expression. b-Gal expression in kidney is clear
and localized only in blood vessels.
Statistics: (A–D) One-way ANOVA with Dunn’s multiple comparison test (**, p , 0.001 versus control WT mice without IP [C]). The F-test results are (A) F
(3,17) ¼ 19.82, p , 0.001.
doi:10.1371/journal.pmed.0050137.g009
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signaling to renal protection during ischemia or IP. For this
purpose, we generated A2BAR bone marrow chimeric mice.
As expected, A2BAR
þ/þ ! A2BAR
þ/þ chimeric mice showed a
similar degree of renal protection (attenuated plasma
creatinine and improved GFR) following IP treatment as
WT mice (Figure 10A and 10B). Moreover, renal protection
by IP was abrogated in A2BAR
 / ! A2BAR
 / mice, similar to
A2BAR
 /  mice (Figure 10A and 10B). Surprisingly, and in
contrast to previous studies showing myeloid A2BAR signal-
ing in vascular inﬂammation [44], renal protection by IP was
conferred solely to renal A2BAR. In fact, A2BAR
 /  !
A2BAR
þ/þ chimeric mice showed a similar degree of renal
protection by IP as A2BAR
þ/þ mice (Figure 10A and 10B). In
Figure 10. Renal Ischemia and Preconditioning in A2BAR Bone Marrow Chimeric Mice
A2BAR bone marrow chimeric mice [A2BAR
þ/þ!A2BAR
þ/þ [WT!WT], A2BAR
 / !A2BAR
 /  [KO!KO], A2BAR
 / !A2BAR
þ/þ [KO!WT] and A2BAR
þ/þ
!A2BAR
 /  [WT!KO]) were generated. Experiments were performed 8 wk following transplantation. Mice underwent right nephrectomy and
underwent 45 min of left renal artery ischemia with or without prior IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion).
Following 24 h of reperfusion time, (A) plasma creatinine and (B) GFRs were measured.
Influence of A2BAR agonist (BAY 60–6583) on renal function in bone marrow chimeric mice exposed to ischemia. A2BAR bone marrow chimeric mice
were subjected to 45 min of ischemia with or without treatment with A2BAR agonist BAY 60–6583 (60 lg/kg intravenous). Following 24 h of
reperfusion, (C) plasma creatinine, (D) GFR, and (E) histological tissue injury (Jablonski index) were obtained.
Statistics: (A–D) One-way ANOVA with Tukey’s post-hoc test was performed (**, p , 0.001 versus the respective group without IP. The F-test results are
(A) F (7,40)¼ 24.82, p , 0.001; (B) F (7,40) ¼ 48.04, p , 0.001; (C) F (3,20) ¼ 15.54, p , 0.001; (D) F (3,20) ¼ 20.88, p , 0.001.
(E) Kruskal-Wallis nonparametric analysis (chi-square¼12, df¼3, p¼0.007) with follow-up pairwise comparisons by Wilcoxon-Mann-Whitney test was
performed with *, p , 0.05 versus WT mice with BAY treatment.
doi:10.1371/journal.pmed.0050137.g010
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A2BAR in Renal Protection from Ischemiacontrast, renal resistance to ischemia was not increased by IP
treatment of A2BAR
þ/þ ! A2BAR
 /  chimeric mice. Taken
together, these studies suggest a critical role of renal A2BARs
(as opposed to hematopoietic) in mediating the protective
effects of IP.
Increased Resistance to Renal Ischemia with A2BAR
Agonist BAY 60–6853 Treatment Requires Renal A2BARs
To further deﬁne the contribution of renal or hemato-
poietic A2BARs to renal protection from ischemia, we next
performed studies of renal ischemia in A2BAR bone-marrow
chimeric mice pretreated with the selective A2BAR agonist
BAY 60–6853. Bone marrow chimeric A2BAR mice expressing
the A2BAR on the tissues but not on their hematopoietic cells
(A2BAR
 /  ! A2BAR
þ/þ mice) showed dramatic improvement
in renal function with BAY 60–6583 pretreatment (60 lg/kg)
as assessed by plasma creatinine, GFR, and renal histology—
similar to A2BAR
þ/þ mice (Figure 10C–10E). In contrast, BAY
60–6583 pretreatment of A2BAR bone marrow chimeric mice
with the A2BAR expressed exclusively on hematopoietic cells
(A2BAR
þ/þ! A2BAR
 / mice) lacked any measurable improve-
ment of renal function during ischemia (Figure 10C–10E).
Together with our studies in A2BAR reporter mice showing
exclusive expression of the renal A2BAR within the vascula-
ture, these data suggest that signaling through the reno-
vascular A2BAR is a critical control point for attenuating
acute renal failure from ischemia.
Renal Ischemia Reperfusion Injury Involves Myeloid
A2AAR Signaling, While Preconditioning Is Conferred to
Renal A2BARs
On the basis of previous studies showing a critical role of
myeloid A2AAR signaling in attenuating renal ischemia
reperfusion injury [29] and the above results, we pursued
the hypothesis that myeloid A2AAR signaling attenuates
renal ischemia-reperfusion injury, while renal A2BAR signal-
ing is important for preconditioning phenomena. For this
purpose, we transplanted A2BAR
 /  or A2BAR
þ/þ mice with
bone marrow from A2AAR
 /  or A2AAR
þ/þ mice. Consistent
with the above hypothesis, these studies revealed that reno-
protection by IP required renal A2BAR signaling, while mice
without a myeloid A2AAR had more severe ischemia
reperfusion injury (Figure 11A and 11B).
Discussion
In the present study, we investigated endogenous pathways
for renal protection from ischemia. For this purpose, we
utilized a recently developed model of renal IP via isolated
renal artery occlusion by use of a hanging weight system,
which allows for highly reproducible renal injury [40]. While
previous studies on IP in the heart have focused on
histological measurements of myocardial cell death or
leakage of myocardial speciﬁc enzymes into the systemic
circulation, this model allowed us to assess the consequences
of IP-treatment on the preservation of speciﬁc renal
functions, such as GFR, urinary sodium or potassium
excretion, or urine production. On the basis of previous
work showing extracellular adenosine generation in renal
protection from ischemia [19,20], we tested the contribution
of signaling through individual ARs to renal protection from
ischemia by IP. Using genetic and pharmacological ap-
proaches, these studies revealed a pivotal role of the
A2BAR. In fact, selective A2BAR agonist treatment provided
a similar degree of renal protection from ischemia as IP
treatment itself, suggesting that A2BAR agonists ‘‘precondi-
tion’’ the kidneys. Finally, the use of a reporter mouse model
and studies in bone marrow A2BAR chimera helped to
pinpoint the source of A2BAR protection to the reno-
vasculature. This vascular phenotype was a surprising ﬁnding,
as previous studies in the heart have conferred precondition-
ing phenomena mainly towards a metabolic adaptation of the
myocardium [27,28,35,36,57]. In contrast, the present studies
have revealed a critical contribution of the reno-vascular
A2BAR to renal IP protection. Taken together, these data
provide what we believe to be a previously not appreciated
role of reno-vascular A2BAR signaling in enhancing renal
resistance to ischemia and provide strong rationale for
therapeutically targeting the A2BAR during renal ischemia.
Presently, the molecular mechanism of how renal A2BAR
signaling attenuates renal injury from ischemia remains
unknown. As previous studies have shown an important role
of erythropoietin in tissue adaptation to hypoxia [58] or
preconditioning [59], it would be tempting to speculate that
extracellular adenosine generation and signaling (e.g.,
through the A2BAR) could inﬂuence renal erythropoietin
secretion, e.g., as part of an autocrine feedback loop.
However, recent work tested the inﬂuence of adenosine
generation and signaling on renal erythropoietin release
using genetic and pharmacological approaches [60,61]. These
studies revealed that targeting extracellular adenosine gen-
eration (cd3
 /  mice) [60,61] or individual ARs (AR
 /  mice)
[61] did not inﬂuence stimulated erythropoietin release.
Taken together these studies rule out a contribution of
extracellular adenosine generation or signaling on renal
erythropoietin release. On the other hand, a study on
extracellular adenosine in hypoxic preconditioning uncov-
ered a novel molecular pathway of how adenosine signaling
through the A2BAR can promote tissue adaptation to limited
oxygen availability [26]. In this study, the authors investigated
hypoxic precondition as a form of endogenous protection
that renders cells tolerant to subsequent and more severe
challenges of hypoxia. In order to deﬁne anti-inﬂammatory
properties of preconditioning, the authors identiﬁed a cluster
of NFjB-regulated genes whose expression was attenuated by
preconditioning. Subsequent studies revealed that precondi-
tioning-elicited protection was conferrable, as a soluble
supernatant from preconditioned cells, and the active
fraction identiﬁed as adenosine. Guided by recent studies
demonstrating bacterial inhibition of NFjB through cullin-1
(Cul-1) deneddylation, they found a dose-dependent dened-
dylation of Cul-1 mediated by signaling through the A2BAR,
suggesting that extracellular accumulation of adenosine and
signaling through the A2BAR suppresses NFjB activity via
deneddylation of Cul-1. These results are consistent with our
present study showing that A2BAR-dependent signaling
pathways are important for the anti-inﬂammatory properties
of renal IP.
However, renal A2BAR signaling could also involve other
(and also faster) mechanisms of renal protection other than
modulating inﬂammation. Based on the fact that dead tissues
may themselves cause the induction of inﬂammation, the
observed inﬂammatory inﬁltrates may well be a result of dead
and dying cells rather than the cause of cell death. Moreover,
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tended to support inﬂammation as an effect rather than a
cause as the receptors responsible for the protection were
found not to be on the marrow-derived cells but on the reno-
vasculature. As such, considerable evidence now indicates that
IP-protection in the heart may be the result of preservation of
the cardiac mitochondria by preventing permeability tran-
sition pore formation, which normally occurs in the ﬁrst
minutes of reperfusion [36,57,62]. Therefore, similar mecha-
nisms could be accounting for the reno-protective effects
observed in the kidneys. Moreover, the fact that abolished
renal protection with A2BAR antagonist treatment and reno-
protective effects with A2BAR agonist treatment are limited
to a time window that ends during early reperfusion (Figures
6 and 7) speaks in favor for such mechanisms.
The present study is consistent with previous work showing
an anti-inﬂammatory role of vascular A2BAR signaling. In
fact, a study by Yang et al. used an ‘‘A2BAR-knockout/
reporter gene-knock-in’’ approach to study the role of the
A2BAR in inﬂammatory models [44]. The authors found
highest expressional levels of the A2BAR in the vasculature
and on macrophages. In addition, genetic deletion of the
A2BAR was associated with low-grade vascular inﬂammation,
augmentation of pro-inﬂammatory cytokines such as TNF-a,
and a consequent down-regulation of IjBa in addition to up-
regulation of adhesion molecules of the vasculature. Con-
sistent with the present study on renal protection by IP,
vascular inﬂammation was signiﬁcantly increased in mice
gene-targeted for the A2BAR [44]. Moreover, the authors
showed that exposure to endotoxin resulted in augmented
pro-inﬂammatory cytokine levels in gene-targeted mice.
However, and in contrast to the present studies showing a
critical role of the reno-vascular A2BAR in providing renal
protection from ischemia, Yang et al. found that bone
marrow (and to a lesser extent vascular) A2BARs regulated
the low grade inﬂammation observed in their studies [44].
The present study on A2BAR signaling during renal
ischemia is consistent with recent work on cardiac generation
and signaling of adenosine [63,64]. For example, two recent
studies provided genetic evidence for extracellular adenosine
generation in cardio-protection by IP [27,28]. In extension of
these ﬁndings, the authors compared preconditioning re-
sponses of gene-targeted mice for each individual AR.
Consistent with the present studies and other studies on
Figure 11. Renal Ischemia and Preconditioning in A2A/A2B AR Bone Marrow Chimeric Mice
A2BAR
þ/þ(A2BWT) or A2BAR
 / (A2BKO) mice underwent lethal radiation followed by bone marrow transplantation with marrow derived from A2AAR
þ/þ
(A2AWT) or A2AAR
 /  (A2AKO) mice. Experiments were performed 8 wk following transplantation. Mice underwent right nephrectomy and underwent
45 min of left renal artery ischemia with or without prior IP (consisting of four cycles of 4 min ischemia followed by 4 min reperfusion). Following 24 h of
reperfusion time, (A) plasma creatinine and (B) GFRs were measured.
Statistics: One-way ANOVA with Tukey’s post-hoc test was performed (**, p , 0.001 versus the respective group with IP; *, p , 0.001 versus
A2AWT!A2BKO). The F-test results are (A) F (7,40) ¼ 32.45, p , 0.001; (B) F (7,40) ¼ 29.67, p , 0.001.
doi:10.1371/journal.pmed.0050137.g011
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found a pivotal role of the A2BAR, revealing that A2BAR
agonist treatment preconditions the myocardium. Other
investigations of renal ischemia and reperfusion injury have
found contributions of the A2AAR [29,51,65]. As such, a series
of studies of renal ischemia and reperfusion in chimeric mice
found that bone marrow-derived cells play an important role
in A2AAR-mediated tissue protection [29,65,66]. Further
work using adoptive transfers into Rag-1
 /  mice revealed
that IFNc produced by CD4
þ T cells appears to be an
important mediator for this complex interplay [66]. Taken
together with results from the present studies, these ﬁndings
suggest a combined role of myeloid A2AARs—predominantly
expressed on T-lymphocytes—and reno-vascular A2BARs in
attenuation of renal ischemia.
In conclusion, the present studies revealed induction and
signaling through the reno-vascular A2BAR as part of an
endogenous pathway to increase renal resistance to ischemia
and attenuate ischemia reperfusion injury. Extensions of
these ﬁndings provide evidence for targeting the A2BAR
therapeutically during renal ischemia. Based on the fact that
the presented data are all derived from murine studies,
further challenges will include the translation from mice to
human. In addition, it will be important to address
pharmacokinetics and additional effects of A2BAR agonist
treatment on coagulation, blood pressure, or pulmonary
function, before such studies can be implemented and tested
in a clinical setting.
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Background. Throughout life, the kidneys perform the essential task of
filtering waste products and excess water from the blood to make urine.
Each kidney contains about a million small structures called nephrons,
each of which contains a filtration unit consisting of a glomerulus (a
small blood vessel) intertwined with a urine-collecting tube called a
tubule. If the nephrons stop working for any reason, the rate at which
the blood is filtered (the glomerular filtration rate or GFR) decreases and
dangerous amounts of waste products such as creatinine build up in the
blood. Most kidney diseases destroy the nephrons slowly over years,
producing an irreversible condition called chronic renal failure. But the
kidneys can also stop working suddenly because of injury or poisoning.
One common cause of ‘‘acute’’ renal failure in hospital patients is
ischemia—an inadequate blood supply to an organ that results in the
death of part of that organ. Heart surgery and other types of surgery in
which the blood supply to the kidneys is temporarily disrupted are
associated with high rates of acute renal failure.
Why Was This Study Done? Although the kidneys usually recover from
acute failure within a few weeks if the appropriate intensive treatment
(for example, dialysis) is provided, acute renal failure after surgery can be
fatal. Thus, new strategies to protect the kidneys from ischemia are badly
needed. Like other organs, the kidneys can be protected from lethal
ischemia by pre-exposure to several short, nonlethal episodes of
ischemia. It is not clear how this ‘‘ischemic preconditioning’’ increases
renal resistance to ischemia but some data suggest that the protection
of tissues from ischemia might involve a signaling molecule called
extracellular adenosine. This molecule binds to proteins called receptors
on the surface of cells and sends signals into them that change their
behavior. There are four different adenosine receptor—A1AR, A2AAR,
A2BAR, and A3AR—and in this study, the researchers use ischemic
preconditioning as an experimental strategy to investigate which of
these receptors protects the kidneys from ischemia in mice, information
that might provide clues about how to protect the kidneys from
ischemia.
What Did the Researchers Do and Find? The researchers first asked
whether ischemic preconditioning protects the kidneys of mice strains
that lack the genes for individual adenosine receptors (A1AR
 / , A2AAR
 / ,
A2BAR
 / ,a n dA3AR
 /  mice) from subsequent ischemia. Using a
hanging-weight system, they intermittently blocked the renal artery of
these mice before exposing them to a longer period of renal ischemia.
Twenty-four hours later, they assessed the renal function of the mice by
measuring their blood creatinine levels, GFRs, and urine production.
Ischemic preconditioning protected all the mice from ischemia-induced
loss of kidney function except the A2BAR
 /  mice. It also prevented
ischemia-induced structural damage and inflammation in the kidneys of
wild-type but not A2BAR
 /  mice. These results suggest that A2BAR may
help to protect the kidneys from ischemia. Consistent with this idea,
ischemic preconditioning did not prevent ischemia-induced renal
damage in wild-type mice treated with a compound that specifically
blocks the activity of A2BAR. However, wild-type mice (but not A2BAR
 / 
mice) treated with an A2BAR agonist (which activates the receptor)
retained their kidney function after renal ischemia without ischemic
preconditioning. Finally, the researchers report that A2BAR has to be
present on the blood vessels in the kidney to prevent ischemia-induced
acute renal failure.
What Do These Findings Mean? These findings suggest that the
protection of the kidneys from ischemia and the renal resistance to
ischemia that is provided by ischemic preconditioning involve adenosine
signaling through A2BAR. They also suggest that adenosine might
provide protection against ischemia-induced damage by blocking
inflammation in the kidney although other possible mechanisms of
action need to be investigated. Importantly, these findings suggest that
A2BAR might be a therapeutic target for the prevention of renal
ischemia. However, results obtained in animals do not always reflect the
situation in people, so before A2BAR agonists can be used to reduce the
chances of patients developing acute renal failure after surgery, these
results need confirming in people and the safety of A2BAR agonists need
to be thoroughly investigated.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050137.
  The US National Institute of Diabetes and Digestive and Kidney
Diseases provides information on how the kidneys work and what can
go wrong with them, including a list of links to further information
about kidney disease
  The MedlinePlus encyclopedia has a page on acute kidney failure (in
English and Spanish)
  Wikipedia has pages on acute renal failure, ischemia, ischemic
preconditioning, and adenosine (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several languages)
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